GlassScriptPhysician profile
Robert Laundra Powell
NPI 1104824382
$2,568.96
in general payments reported to CMS, 2019-2025
28 companies · $732 in 2025
The $732 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $369 · 2023: $409 · 2024: $522 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.31 | 2021-2025 | |
| Novo Nordisk INC | $597.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $205.14 | 2025 | |
| Pfizer INC. | $200.11 | 2021-2025 | |
| Dexcom, INC. | $131.48 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.61 | 2021-2025 | Xifaxan |
| Amgen INC. | $114.52 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $72.17 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $59.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $45.72 | 2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.94 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $39.94 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.11 | 2022 | |
| Lilly USA, LLC | $30.92 | 2021-2024 | Zepbound, Jardiance |
| Ani Pharmaceuticals, INC. | $29.61 | 2025 | Purified Cortrophin Gel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.83 | 2022 | |
| Csl Behring | $25.09 | 2024 | Kcentra |
| Abbott Laboratories | $22.50 | 2021 | |
| Corcept Therapeutics | $20.08 | 2025 | Korlym |
| Exact Sciences Corporation | $19.90 | 2025 | The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $15.97 | 2021 | |
| Cranial Technologies, INC | $14.62 | 2021 | |
| Inspire Medical Systems, INC. | $14.53 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $13.84 | 2024 | Farxiga |
| Phadia US INC. | $13.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.96 | 2022 | |
| Astellas Pharma US INC | $11.29 | 2021 | |
| Genentech USA, INC. | $5.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.